Nycomed's Omniscan approved in Japan

Hafslund Nycomed's Omniscan MRI contrast agent has been certified

for marketing in Japan, the Oslo, Norway, company reported this

month. Nycomed said that Omniscan will be launched by Daiichi

Pharmaceutical, Nycomed's Japanese licensee, as soon as final

price approval is granted by Japanese authorities. Nycomed added

that it has submitted an application for marketing approval in

Japan for Visipaque, its third-generation x-ray contrast agent.